Gaillard M, Tranchart H, Dagher I. Laparoscopic liver resections for hepatocellular carcinoma: Current role and limitations[J]. World J Gastroenterol, 2014, 20(17): 4892-4899. [2]Nomoto S, Hishida M, Inokawa Y, et al. Management of hepatocellular carcinoma should consider both tumor factors and background liver factors[J]. Hepatobiliary Surg Nutr, 2014, 3(2): 82-85. [3]Imai S, Armstrong C M, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase[J]. Nature, 2000, 403(6771): 795-800. [4]Pantazi E, Zaouali M A, Bejaoui M, et al. Role of sirtuins in ischemia-reperfusion injury[J]. World J Gastroenterol, 2013, 19(43): 7594-7602. [5]Rothgiesser K M, Erener S, Waibel S, et al. SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310[J]. J Cell Sci, 2010, 123(Pt 24): 4251-4258. [6]Bosch-Presegue L, Vaquero A. The dual role of sirtuins in cancer[J]. Genes Cancer, 2011, 2(6): 648-662. [7]Inoue T, Hiratsuka M, Osaki M, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress[J]. Oncogene, 2007, 26(7): 945-957. [8]Dryden S C, Nahhas F A, Nowak J E, et al. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle[J]. Mol Cell Biol, 2003, 23(9): 3173-3185. [9]宋春丽, 任吉华, 冉龙宽, 等. SIRT2沉默对肝癌细胞的迁移和侵袭能力的影响[J]. 第三军医大学学报, 2013, 35(24): 2634-2638. [10]Chen Z, Ma T, Huang C, et al. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells[J]. Cell Signal, 2013, 25(12): 2693-2701. [11]Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead[J]. Front Pharmacol, 2012, 3: 4. [12]Wang R H, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice[J]. Cancer Cell, 2008, 14(4): 312-323. [13]Chen J, Zhang B, Wong N, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth[J]. Cancer Res, 2011, 71(12): ？4138-4149？. [14]Huffman D M, Grizzle W E, Bamman M M, et al. SIRT1 is significantly elevated in mouse and human prostate cancer[J]. Cancer Res, 2007, 67(14): 6612-6618. [15]Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease[J]. Arch Dermatol Res, 2007, 299(2): 103-106. [16]Kim H S, Vassilopoulos A, Wang R H, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity[J]. Cancer Cell, 2011, 20(4): 487-499. [17]Li Y, Matsumori H, Nakayama Y, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis[J]. Genes Cells, 2011, 16(1): 34-45. [18]Lee J M, Yang J, Newell P, et al. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation[J]. Cancer Lett, 2014, 343(1): 90-97. [19]Kaldis P, Pagano M. Wnt signaling in mitosis[J]. Dev Cell, 2009, 17(6): 749-750.
[2]
金世龙,黄中荣,陈华,等.HuH7细胞系CD13+CD133+HCC细胞分选及CSCs特性分析[J].第三军医大学学报,2012,34(16):1658. Jin Shilong,Huang Zhongrong,Chen Hua,et al.Sorting and cancer stem cell characteristic analysis of CD13+CD133+HCC cells in HuH7 cell line[J].J Third Mil Med Univ,2012,34(20):1658. [2]金世龙,余天雾,黄中荣,等.As2O3在HuH7及CD13+CD133+LCSCs增殖和分化中作用的初步观察[J].第三军医大学学报,2012,34(18):1857. Jin Shilong,Yu Tianwu,Huang Zhongrong,et al.Role of arsenic trioxide in proliferation of HuH7 cells and differentiation of CD13+CD133+ LCSCs[J].J Third Mil Med Univ,2012,34(20):1857. [3]庞林宾,王洪林,王晔飞,等.JAK2/STAT3通路在肝癌细胞侵袭及血管生成拟态中的作用[J].第三军医大学学报,2012,34(18):1862. Pang Linbin,Wang Honglin,Wang Yefei,et al.Role JAK2/STAT3 signaling pathway in invasion and vascular mimicry of liver cancer cells[J].J Third Mil Med Univ,2012,34(20):1862. [4]熊震,汤旭东,房殿春,等.人肝素酶RNAi序列的筛选及鉴定[J].第三军医大学学报,2007,29(20):1929. XIONG Zhen,TANG Xu-dong,FANG Dian-chun,et al.Screening and identification of heparanase RNAi sequence[J].J Third Mil Med Univ,2007,29(20):1929. [5]向征,张才全,汤为学.TSG101-siRNA对肝癌耐药细胞株QGY/CDDP的逆转作用[J].第三军医大学学报,2008,30(02):170. XIANG Zheng,ZHANG Cai-quan,TANG Wei-xue.Effect of tumor susceptibitity gene 101-siRNA eukaryotic expression vector and cisplatin on proliferation of QGY/CDDP[J].J Third Mil Med Univ,2008,30(20):170. [6]郑继军,王阁,邓婧,等.PD98059对肝癌HepG2细胞Tec信号转导作用的初步研究[J].第三军医大学学报,2006,28(02):136. [7]郑继军,王阁.肝癌粘附转移中相关整合素的作用研究现状[J].第三军医大学学报,2006,28(02):176. [8]张百红,贺佳,朱德增,等.一个新的肝癌分期系统的构建[J].第三军医大学学报,2006,28(03):253. [9]李宁,候丽娟.自体CIK细胞治疗肝癌患者的护理[J].第三军医大学学报,2006,28(05):485. [10]戴纪刚,肖颖彬,闵家新,等.高低转移小鼠肝癌细胞线粒体DNA遗传变异的研究[J].第三军医大学学报,2006,28(20):2030.
